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BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) is a major type of liver cancer 
associated with high mortality. Prognosis is poor in HCC patients largely because of late 
diagnosis and limitations in treatment options. Therefore, this study aims to identify alternative 
target for HCC in hope to offer new treatments to patients. Cadherin-17 (CDH17) has been 
identified as an oncofetal molecule of HCC and that a suppression of its expression by RNA 
interference (RNAi) leads to anti-tumorigenesis. To supplement the drawbacks associated with 
the use of RNAi approach in biotherapy, we developed specific antibody against CDH17 for 
achieving similar purpose. METHODS: Hybridoma cell clones capable of secreting antibodies 
against ectodomains of human CDH17 were injected subcutaneously into nude mice to stimulate 
ascites production, after which monoclonal antibody against CDH17 (anti-CDH17) was tested on 
purity, specificity and immunogenicity. In vitro functional assays were conducted to assess the 
effect of anti-CDH17 treatment in altering the tumor phenotypes of HCC cells. Besides, 
subcutaneous tumor xenograft model was developed for examining the tumor-suppressing 
capacities of anti-CDH17 treatment alone or in combined with chemotherapeutic drug cisplatin. 
For tumor xenografts from anti-CDH17 treatment group, biochemical analyses examining cell 
proliferation, extent of apoptosis and effects on CDH17-b-catenin axis were analyzed. RESULTS: 
Anti-CDH17 derived from mouse ascites associated with high purity, specificity and 
immunogenicity in detecting CDH17 and demonstrated a profound effect in suppressing CDH17. 
Treatment of anti-CDH17 suppressed proliferation, migration, invasion and colony formation of 
cultured CDH17-expressing HCC cells (MHCC97L/97L and MHCC97H/97H), but not CDH17-
deficient cells. When mice bearing 97L-derived subcutaneous tumors were treated with anti-
CDH17, regression in tumor sizes accompanying with less chance of developing lung metastasis 
were observed and more prominent effects were resulted in combined with cisplatin. This anti-
tumor effect of anti-CDH17 treatment was linked to an inactivation of the CDH17-b-catenin axis 
frequently found in CDH17-expressing HCC. Tumor xenografts subjected to anti-CDH17 
treatment associated with a reduced tumor cell proliferation and an increased level of apoptosis. 
CONCLUSIONS: Anti-CDH17 treatment inactivates CDH17-b-catenin axis and leads to anti-
tumorigenic effects in CDH17-expressing HCC cells and xenografts, suggesting its future 
development as alternative medicine for HCC. 
